Machine Learning Natural Language Processing Data Platforms Data Analytics Market Trends Product Promotion Business Applications Automation Software Development Data Management
The stock-heavy offer would fold Personalis' NeXT Personal MRD test into Tempus' AI oncology platform pending shareholder and regulatory approval.